CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 132 enrolled
Drug / intervention
Mometasone Furoate nasal spray +1 moredrug
Likely dose
Mometasone Furoate nasal spray 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00552032
NCT00552032Phase 3Completed
CompareCT.gov

A Double-blind Placebo-controlled, Randomized, Parallel-group, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy SNORE Study

Organon and Co·interventional·Posted Nov 1, 2007·Updated May 20, 2024

In Brief

A Phase 3 clinical trial evaluating Mometasone Furoate nasal spray and Placebo for Adenoids Hypertrophy. Completed, enrolled 132 participants.

Detailed Summary

The purpose of this study is to determine whether 8 weeks treatment with mometasone furoate nasal spray (MFNS), twice daily, is safe and effective in treating adenoid hypertrophy in children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenoids Hypertrophy
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 1, 2007
Enrollment StartAug 1, 2007
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.7 years ago

Interventions

Mometasone Furoate nasal spraydrug

Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).

Placebodrug

Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).